Skip to main content
. 2015 Mar 10;23(5):907–917. doi: 10.1038/mt.2015.22

Figure 3.

Figure 3

αCD22-Pol950-BIM conjugates enhance blood circulation half-life, peptide stability, and tumor distribution. The blood clearance of dual-radiolabeled αCD22-Pol950-BIM and αCD22-Pol300-BIM conjugates in comparison to free αCD22 or BIM were monitored through (a) 3H-labeled αCD22 and (b) 14C-labeled BIM (n = 3). Solid lines represent a two compartment open model with 1/y2 weighting. (c) Stability of disulfide-linked BIM on Pol950 and Pol300 was measured by following the BIM to αCD22 ratio in the blood (initial ratio = 90:1). Data in plots a and b represent the mean ± SD. (d) Biodistribution of αCD22-Pol950-BIM and αCD22-Pol300-BIM conjugates after 24 hours was measured by following 3H-αCD22 (n = 5). Asterisks represent statistical significance (P < 0.05) by two-way ANOVA. Data represent mean ± SD. (e–f) Representative fluorescence microscopy images of tumor sections 48 hours after administration of Alexa Fluor 647-labeled Pol950 and Pol300 without BIM peptide. Treatments include e PBS, f αCD22-Pol300, and (g) αCD22-Pol950 (n = 3). Nuclei stained with DAPI (blue) and polymer labeled with Alexa Fluor 647 (green). Scale bar = 15 nm.